Composition for inhibiting activity of 5 alpha-reductase and application thereof
A combination of zinc hyaluronic acid and vitamin B6, through synergistic effects, was prepared into a scalp care complex solution, which solved the adverse reaction problem of existing inhibitors and achieved effective inhibition of 5α-reductase activity, thus improving scalp health.
Patent Information
- Application Number
- CN202410584731.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-11
- Publication Date
- 2025-11-11
AI Technical Summary
Existing 5α-reductase inhibitors have adverse reactions in clinical applications and are difficult to effectively inhibit 5α-reductase activity, leading to excessively high DHT levels and causing pathological changes such as acne, seborrheic alopecia, seborrheic dermatitis, benign prostatic hyperplasia, and prostate cancer.
A combination of zinc hyaluronic acid and vitamin B6 is used to synergistically inhibit 5α-reductase activity and is prepared into a scalp care compound solution for scalp care.
It significantly inhibits 5α-reductase activity, increases scalp moisture content, reduces sebum secretion, promotes dermal papilla cell proliferation, and relieves scalp dryness and excessive sebum secretion.
Smart Images
Figure BDA0004835399800000071 
Figure BDA0004835399800000101 
Figure BDA0004835399800000111
Abstract
Description
Technical Field
[0001] This application relates to the field of hair care technology, and more particularly to a composition that inhibits 5α-reductase activity and its use. Background Technology
[0002] 5α-reductase is a membrane protease dependent on reduced coenzyme II (NADPH) that catalyzes the conversion of testosterone (T) to dihydrotestosterone (DHT). Human 5α-reductase has two isoenzymes, type I and type II. Type I is mainly distributed in the liver, skin, sebaceous glands, and hair follicles, while type II is mainly distributed in the prostate and reproductive tissues. Studies have shown that high levels of DHT in the prostate and skin can cause various pathological changes, such as acne, seborrheic alopecia, seborrheic dermatitis, benign prostatic hyperplasia, and prostate cancer. Therefore, effectively reducing DHT levels in the body is one of the effective methods for preventing and treating these diseases.
[0003] 5α-reductase inhibitors are a class of substances that reduce DHT production in the body by inhibiting the activity of 5α-reductase. Currently developed 5α-reductase inhibitors include both steroidal and non-steroidal types, and have achieved good results in the prevention and treatment of acne, seborrheic alopecia, benign prostatic hyperplasia, and prostate cancer. However, these commonly used chemotherapy drugs have all shown certain adverse reactions in clinical practice. Summary of the Invention
[0004] In view of the above-mentioned problems, this application provides a composition for inhibiting 5α-reductase activity, wherein the various components of the composition work synergistically to safely and effectively inhibit 5α-reductase activity.
[0005] The specific technical solution of this application is as follows:
[0006] 1. A composition for inhibiting 5α-reductase activity, comprising zinc hyaluronic acid and vitamin B6, wherein the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.1-3.5):(0.005-1.3).
[0007] 2. The composition according to claim 1, wherein the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.2-3):(0.01-1).
[0008] 3. The composition according to claim 1 or 2, wherein the molecular weight of the zinc hyaluronic acid is 1-500 kDa.
[0009] 4. A scalp care compound solution comprising the composition described in any one of items 1-3.
[0010] 5. The scalp care complex solution according to claim 4, wherein the zinc hyaluronic acid is 0.01-5% by mass percentage in the scalp care complex solution; and / or
[0011] The vitamin B6 content is 0.005-2%.
[0012] 6. The scalp care complex solution according to item 4 or 5, wherein the scalp care complex solution further comprises other active ingredients and / or excipients.
[0013] 7. Use of the composition described in any one of items 1-3 or the scalp care compound solution described in any one of items 4-6 to inhibit 5α-reductase activity.
[0014] The effects of the invention
[0015] The zinc hyaluronic acid and vitamin B6 in the composition described in this application work synergistically to safely and effectively inhibit 5α-reductase activity. Furthermore, when the scalp care compound solution is prepared using the composition described in this application, it can increase the moisture content of the scalp stratum corneum, relieve scalp dryness, inhibit excessive sebum secretion, and enhance the proliferation of dermal papilla cells. Detailed Implementation
[0016] The present application will now be described in detail with reference to the described embodiments. Although specific embodiments of the present application are shown, it should be understood that the present application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this application will be thorough and complete, and will fully convey the scope of the present application to those skilled in the art.
[0017] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.
[0018] This application provides a composition for inhibiting 5α-reductase activity, comprising zinc hyaluronic acid and vitamin B6, wherein the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.1-3.5):(0.005-1.3). In some embodiments, the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.2-3):(0.01-1).
[0019] The composition described in this application contains zinc hyaluronic acid and vitamin B6, which can synergistically enhance the effect and thus inhibit 5α-reductase activity.
[0020] The mass ratio of zinc hyaluronic acid to vitamin B6 (m) 透明质酸锌 :m 维生素B6 The values can be 0.1:0.005, 0.1:0.01, 0.1:0.05, 0.1:0.1, 0.1:0.5, 0.1:0.8, 0.1:1.0, 0.1:1.3, 0.2:0.005, 0.2:0.01, 0.2:0.05, 0.2:0.1, 0.2:0.5, 0.2:0.8, 0.2:1.0, 0.2:1.3, 0.5:0.005, 0.5:0.01, 0.5:0.05, 0.5:0.1, 0.5:0.5, 0.5:0.8, 0.5:1.0, 0.5:1.3, 1:0.005, 1:0.01, 1:0.05, 1:0.1, 1:0.5, 1:0.8, 1:1.0, 1:1.3, 2:0.005, 2:0.01, 2:0.05, 2:0.1, 2:0.5, 2:0.8, 2:1.0, 2:1.3, 3:0.005, 3:0.01, 3:0.05, 3:0.1, 3:0.5, 3:0.8, 3:1.0, 3:1.3, 3.5:0.005, 3.5:0.01, 3.5:0.05, 3.5:0.1, 3.5:0.5, 3.5:0.8, 3.5:1.0, 3.5:1.3, etc.
[0021] In some embodiments, the molecular weight of the zinc hyaluronic acid is 1-500 kDa.
[0022] For example, the molecular weight of the zinc hyaluronic acid can be 1kDa, 5kDa, 10kDa, 50kDa, 100kDa, 150kDa, 200kDa, 250kDa, 300kDa, 350kDa, 400kDa, 450kDa, 500kDa, etc.
[0023] In some embodiments, the 5α-reductase is a type I 5α-reductase.
[0024] The compositions described in this application may incorporate excipients and active ingredients commonly used in the art. This application does not impose any limitations on the excipients and active ingredients used; they can be conventionally selected as needed.
[0025] This application provides the use of the above composition in inhibiting 5α-reductase activity.
[0026] This application provides the use of the above composition in the preparation of products that inhibit 5α-reductase activity.
[0027] This application provides the use of vitamin B6 and zinc hyaluronic acid in inhibiting 5α-reductase activity.
[0028] The vitamin B6 and zinc hyaluronic acid provided in this application have a synergistic effect and can significantly inhibit the activity of 5α-reductase.
[0029] In some embodiments, the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.1-3.5):(0.005-1.3). In some embodiments, the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.2-3):(0.01-1).
[0030] This application provides a scalp care compound solution comprising any of the compositions described above.
[0031] This application demonstrates that by using a composite solution containing the above-described composition, the scalp's moisture content can be increased, oil content reduced, resulting in significant oil control, and the proliferation of hair papilla cells can be promoted.
[0032] In some embodiments, the zinc hyaluronic acid is 0.01-5% by mass percentage in the scalp care complex solution; and / or
[0033] The vitamin B6 content is 0.005-2%. In some embodiments, the scalp care complex solution also contains other active ingredients and / or excipients.
[0034] For example, the zinc hyaluronic acid is 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, etc., by mass percentage in the scalp care compound solution;
[0035] The vitamin B6 can be 0.005%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, etc.
[0036] In this application, no restrictions are placed on the method of using the scalp care compound solution. It can be used in accordance with conventional methods in the art, such as injecting or applying the compound solution to the scalp.
[0037] This application provides the use of the above-mentioned scalp care compound solution in inhibiting 5α-reductase activity.
[0038] Example
[0039] This application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. Reagents or instruments used, unless otherwise specified, are all commercially available conventional reagent products.
[0040] Example 1
[0041] A composition was obtained by mixing 0.2g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B6.
[0042] Example 2
[0043] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B6.
[0044] Example 3
[0045] A composition was obtained by mixing 1g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B6.
[0046] Example 4
[0047] A composition was obtained by mixing 3g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B6.
[0048] Example 5
[0049] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 50kDa) and 0.01g of vitamin B6.
[0050] Example 6
[0051] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 50kDa) and 0.5g of vitamin B6.
[0052] Example 7
[0053] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 50kDa) and 1g of vitamin B6.
[0054] Example 8
[0055] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 500kDa) and 0.1g of vitamin B6.
[0056] Example 9
[0057] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 1kDa) and 0.1g of vitamin B6.
[0058] Example 10
[0059] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 200kDa) and 0.1g of vitamin B6.
[0060] Comparative Example 1
[0061] 0.2g of zinc hyaluronic acid (molecular weight 50kDa).
[0062] Comparative Example 2
[0063] 0.5g of zinc hyaluronic acid (molecular weight 50kDa).
[0064] Comparative Example 3
[0065] 1g of zinc hyaluronic acid (molecular weight 50kDa).
[0066] Comparative Example 4
[0067] 3g of zinc hyaluronic acid (molecular weight 50kDa).
[0068] Comparative Example 5
[0069] 5g of zinc hyaluronic acid (molecular weight 50kDa).
[0070] Comparative Example 6
[0071] 0.01g of vitamin B6.
[0072] Comparative Example 7
[0073] 0.1g of vitamin B6.
[0074] Comparative Example 8
[0075] 0.5g of vitamin B6.
[0076] Comparative Example 9
[0077] 1g of vitamin B6.
[0078] Comparative Example 10
[0079] A composition was obtained by mixing 0.5g of sodium hyaluronate (molecular weight 50kDa) and 0.1g of vitamin B6.
[0080] Comparative Example 11
[0081] A composition was obtained by mixing 0.5g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B2.
[0082] Comparative Example 12
[0083] A composition was obtained by mixing 5g of zinc hyaluronic acid (molecular weight 50kDa) and 0.1g of vitamin B6.
[0084] Comparative Example 13
[0085] 0.5g of zinc sulfate.
[0086] Comparative Example 14
[0087] A composition is obtained by mixing 0.5g of zinc sulfate and 0.5g of vitamin B6.
[0088] Comparative Example 15
[0089] A composition was obtained by mixing 0.5g of sodium hyaluronate (molecular weight 50kDa), 0.5g of zinc sulfate and 0.5g of vitamin B6.
[0090] Table 1. Content of each component in the examples and comparative examples.
[0091]
[0092]
[0093] Experiment Example 1: Assay for Inhibition of 5α-Reductase Activity
[0094] 5α-Reductase uses testosterone as a substrate and NADPH as a hydrogen donor to catalyze the conversion of testosterone to DHT, leading to excessive sebum secretion. Therefore, the activity of 5α-reductase can be reflected by detecting changes in the amount of testosterone as a substrate using high-performance liquid chromatography (HPLC).
[0095] The compositions of Examples 1-10 and the components of Comparative Examples 1-15 were dissolved in 50 ml of water for injection, stirred until they were evenly dissolved, and then diluted to 100 ml with water for injection as the test sample.
[0096] The enzyme reaction system was as follows: 300 μL of PBS buffer (pH 7.4), 10 μL of 5 mg / mL 5α-reductase, 50 μL of the sample to be tested, 100 μL of 2 mmol / L NADPH, 50 μL of 2 mmol / L testosterone, and 0.35 mg / mL dutasteride (Sichuan Weikeqi Biotechnology Co., Ltd.), as shown in Table 2. The mixture was reacted at 37℃ for 30 min, and the reaction was terminated by adding 1 ml of pre-cooled methanol. After mixing, the mixture was centrifuged at 10000 r / min for 5 min. The supernatant was collected and filtered through a 0.22 μm filter membrane. High-performance liquid chromatography (HPLC) was then performed (column: Alltima C18 column (150 mm × 4.6 mm, 5 μm); mobile phase: A: methanol, B: pure water; gradient elution: 0–3 min, 59% A; 3–7 min, 59%–87% A; 7–11 min, 87% A; 11–13 min, 87%–59% A; 13–23 min, 59% A; flow rate: 1.0 mL / min). －1 The detection wavelength was 242 nm; the injection volume was 20 μL; and the column temperature was room temperature. All solutions used before injection were filtered through a 0.22 μm nylon membrane. The residual testosterone concentration was detected, and the inhibition rate was calculated using the formula below. The inhibition rate results are shown in Table 3.
[0097] Inhibition rate (%) = (Change in testosterone concentration in blank control - Change in testosterone concentration in sample tube) / Change in testosterone concentration in blank tube × 100
[0098] Table 2 5-α reductase reaction system
[0099] reagents Blank control group Positive control group Sample group to be tested 5α-Reductase 10μL 10μL 10μL PBS buffer 300μL 290μL 250μL testosterone 50μL 50μL 50μL NADPH 100μL 100μL 100μL Duta Xiong'an —— 10μL —— Sample to be tested —— —— 50μL
[0100] Table 3 Results of 5-α reductase inhibition rate
[0101] Group Inhibition rate / % Example 1 82.32 Example 2 85.36 Example 3 89.98 Example 4 88.54 Example 5 84.18 Example 6 86.75 Example 7 87.01 Example 8 80.76 Example 9 81.35 Example 10 83.57 Comparative Example 1 49.86 Comparative Example 2 51.66 Comparative Example 3 61.88 Comparative Example 4 65.29 Comparative Example 5 70.76 Comparative Example 6 4.85 Comparative Example 7 5.13 Comparative Example 8 5.09 Comparative Example 9 5.21 Comparative Example 10 9.56 Comparative Example 11 51.78 Comparative Example 12 78.37 Comparative Example 13 40.32 Comparative Example 14 71.37 Comparative Example 15 72.05
[0102] As can be seen from the experimental results in Table 3, the inhibition rates of 5-α reductase in Examples 1-10 were all above 80%, significantly higher than those in Comparative Examples 1-15. In Comparative Example 10, replacing zinc hyaluronic acid with sodium hyaluronate in Example 2 significantly reduced the inhibitory effect on 5-α reductase, indicating that sodium hyaluronate and zinc hyaluronate have different and significant effects in inhibiting 5-α reductase activity. Replacing zinc hyaluronate with conventional sodium hyaluronate in inhibiting 5-α reductase activity was unpredictable. In Comparative Example 11, replacing vitamin B6 with vitamin B2 in Example 2 also significantly reduced the inhibitory effect on 5-α reductase, indicating that not all B vitamins can synergistically inhibit 5-α reductase activity with zinc hyaluronate. While Comparative Example 14, using a combination of zinc sulfate and vitamin B6, and Comparative Example 15, using a combination of sodium hyaluronate, zinc sulfate, and vitamin B6, also showed some inhibitory effect on 5-α reductase activity, the effect was far less significant than that of the examples containing the zinc hyaluronate composition in this application.
[0103] To further verify the synergistic effect between zinc hyaluronic acid and vitamin B6, the inventors used the King's formula: Q = E(a + b) / (Ea + Eb - Ea × Eb) (where Q < 0.55 indicates significant antagonism, Q = 0.55 - 0.85 indicates antagonism, Q = 0.85 - 1.15 indicates addition, and Q > 1.15 indicates enhancement).
[0104] For example, when the amount of zinc hyaluronic acid added is 0.2g, the 5-α reductase inhibition rate is 49.86%, as in Comparative Example 1; when the amount of vitamin B6 added is 0.1g, the 5-α reductase inhibition rate is 5.13%, as in Comparative Example 7; when the combined amount of zinc hyaluronic acid added is 0.2g and the amount of vitamin B6 added is 0.1g, the 5-α reductase inhibition rate is 82.32%, as in Example 1.
[0105] Ea represents the 5-α reductase inhibition rate when the amount of zinc hyaluronic acid added is 0.2g, which is 49.86%.
[0106] Eb represents the 5-α reductase inhibition rate when vitamin B6 is added at a concentration of 0.1g, which is 5.13%.
[0107] E(a+b) represents the 5-α reductase inhibition rate of a combination of 0.2g of zinc hyaluronic acid and 0.1g of vitamin B6, which is 82.32%.
[0108] Substituting into the formula, we get:
[0109] Q=E(a+b) / (Ea+Eb-Ea×Eb)=0.8232 / (0.4986+0.0513-0.4986×0.0513)=1.57
[0110] Similarly, the Q values of each combination of Example 2 and Comparative Examples 2 and 7, Example 3 and Comparative Examples 3 and 7, Example 4 and Comparative Examples 4 and 7, Example 5 and Comparative Examples 2 and 6, Example 6 and Comparative Examples 2 and 8, Example 7 and Comparative Examples 2 and 9, and Comparative Example 12 and Comparative Examples 5 and 7 were obtained using the same formula as above.
[0111] The measurement results are shown in Table 4.
[0112] Table 4
[0113]
[0114]
[0115] As can be seen from Table 4, except for Comparative Example 12 and Comparative Examples 5 and 7, the Q values of all other groups are greater than 1.15, which means that the combination of zinc hyaluronic acid and vitamin B6 described in this application produces a synergistic effect within a certain ratio range.
[0116] Experiment Example 2: Preparation of Composite Solution and Determination of its Properties
[0117] 1. Preparation of the composite solution:
[0118] A. First, measure a certain amount of water for injection, add sodium hydroxide and folic acid, and stir until completely dissolved to obtain a buffer solution;
[0119] B. Add arginine, glycine, glutamic acid, tyrosine, glutamine, ornithine, biotin, vitamin B6, calcium pantothenate, HEPES (pH adjuster), and sodium chloride to the above buffer solution, and make up to 1000g with water for injection. Stir until fully dissolved, adjust the pH of the solution to about 7.5, and the osmotic pressure to about 300 mosmol / kg. Then filter the solution through a 0.22μm filter membrane to obtain the filtrate. Next, add zinc hyaluronic acid and stir until completely dissolved.
[0120] C. Fill into vials, seal, and sterilize at 121℃ with F0 (F0 is the time (min) equivalent to the sterilization effect produced at a certain sterilization temperature (T) with Z of 10℃ as the sterilization effect produced at 121℃ with Z of 10℃) greater than 8 to obtain a scalp care compound solution. The percentage of each component is shown in Table 5.
[0121] Table 5. Dosage of each component in the composite solution
[0122]
[0123]
[0124] 2. Performance Measurement
[0125] A. Determination of stratum corneum moisture content
[0126] A randomized, double-blind, controlled study was conducted, selecting 20 participants with healthy scalps, aged 20-45 years (10 males and 10 females), divided into two groups of 10 each, with an equal gender distribution. Before the experiment, the scalp stratum corneum moisture content of each participant was measured using a Corneometer CM825MDD4 digital skin moisture analyzer (CK, Germany). The results are shown in Table 6. During the experiment, the participants received scalp injections of the aforementioned compound solution, one vial (5ml) per injection, for a total of 6 injections per course, with an interval of 6 days between each injection. The stratum corneum moisture content was measured at 2 weeks and 8 weeks after the last injection, and the average value was taken from each group. The control group did not receive injections, and its results are shown in Table 6. The results showed that the scalp care compound solution significantly increased scalp moisture content.
[0127] Table 6. Moisture content of the stratum corneum
[0128] Group 0 days Two weeks after the last injection 8 weeks after the last injection Example 6 group 29.15±2.45 46.28±2.01 47.3±3.01 Blank control group 29.69±2.89 30.34±2.76 29.58±3.63
[0129] B. Oil control effect
[0130] The sebum content of the scalp of the test subjects in the above experimental cases was measured using a Sebumeter SM815 sebum analyzer and recorded as the sebum content on day 0. After the last injection, the sebum content was measured at week 4 and week 12 and the data were recorded. The results are shown in Table 7.
[0131] Table 7 Oil Control Effect
[0132] Group 0 days 4 weeks after the last injection 12 weeks after the last injection Example 6 group 119.32±3.11 86.39±4.12 83.12±4.09 Blank control group 109.99±3.78 110.37±4.57 108.78±3.45
[0133] The results showed that the oil content was greatly reduced after using the above-mentioned composite solution, indicating that the composite solution described in this application has an oil control effect.
[0134] C. Evaluation of the effect on promoting the proliferation of dermal papilla cells
[0135] Human dermal papilla cells (HDP) in the logarithmic growth phase (purchased from Qingqi (Shanghai) Biotechnology Development Co., Ltd.) were seeded at an appropriate density into 96-well plates, with 100 μL seeded per well. The culture medium was standard DMEM high-glucose medium containing 10% fetal bovine serum. The seeded cell plates were placed in an incubator at 37°C and 5% CO2 for 24 h. The above compound solution was diluted to a 20% concentration with serum-free medium and sterilized by filtration through a 0.22 μm filter membrane before use. After 24 hours of routine cell culture, the old culture medium was discarded, and the experimental group was replaced with 100 μL of sample (the above-mentioned composite solution). The negative control group was added with an equal volume of culture medium. After 24 hours of culture, the sample solution was discarded, and 10% WST-1 solution (Beijing Bio-Lab Technology Co., Ltd.) prepared with serum-free culture medium was added to each well. The cells were then placed in a cell culture incubator and cultured for another 3 hours. The absorbance was measured at 450 nm using an ELISA reader (Infinite, Teco China), and the relative proliferation rate was calculated. The relative proliferation rate (RGR) was the ratio of the absorbance of the experimental group to that of the negative control group. The results are shown in Table 8.
[0136] Table 8. Statistics on the effects of the examples and comparative products on the proliferation of dermal papilla cells.
[0137] Group absorbance value Relative Growth Rate (RGR) Example 6 group 0.6865 122.18 negative control group 0.5567 ——
[0138] As can be seen from Table 8, the composite solution described in this application can promote the proliferation of human hair papilla cells.
[0139] In summary, the synergistic effect of zinc hyaluronic acid and vitamin B6 in the composition described in this application can significantly inhibit the activity of 5α-reductase. When used to prepare a scalp care compound solution, it can increase the moisture content of the scalp stratum corneum, relieve scalp dryness, inhibit excessive sebum secretion, and enhance the proliferation of dermal papilla cells.
[0140] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.
Claims
1. A composition for inhibiting 5α-reductase activity, comprising zinc hyaluronic acid and vitamin B6, wherein the mass ratio of zinc hyaluronic acid to vitamin B6 is (0.1-3.5):(0.005-1.3).
2. The composition according to claim 1, wherein, The mass ratio of zinc hyaluronic acid to vitamin B6 is (0.2-3):(0.01-1).
3. The composition according to claim 1 or 2, wherein, The molecular weight of the zinc hyaluronic acid is 1-500 kDa.
4. A scalp care complex solution comprising the composition according to any one of claims 1-3.
5. The scalp care compound solution according to claim 4, wherein, The zinc hyaluronic acid is 0.01-5% by mass percentage in the scalp care complex solution; and / or The vitamin B6 content is 0.005-2%.
6. The scalp care compound solution according to claim 4 or 5, wherein, The scalp care complex solution also contains other active ingredients and / or excipients.
7. Use of the composition according to any one of claims 1-3 or the scalp care compound solution according to any one of claims 4-6 for inhibiting 5α-reductase activity.